Market by Drug Type, Technology, Service, End-User, and Country | Forecast 2019-2028
According to research by Triton, North America’s drug discovery market is expected to grow significantly in terms of revenue at a CAGR of 6.57% for the forecasting years 2019-2028.
Report scope can be customized per your requirements. Request For Customization
Countries that have been
covered in the drug discovery market in North America are:
• The United States
• Canada
The American Cancer Society
(ACS) estimates that, in 2020, an estimated 1.8 million people will be
diagnosed with cancer in the United States, with around 606,520 cancer deaths.
This has led to increased investments in lead optimization to enhance
therapeutic value, and, in turn, provide patients with efficient & targeted
therapies. According to US FDA’s data, the Center for Drug Evaluation and
Research (CDER) had approved 40 novel drugs as of September 2020. These were
approved as new molecular entities (NMEs) under New Drug Applications (NDAs) or
as new therapeutic biologics under Biologics License Applications (BLAs).
Overall, 31,468 patients took part in these trials. This shows that the US is
focusing on R&D activities to meet the rising demand from its citizens for
better and effective drugs. This is expected to augment the growth of the
nation’s drug discovery market.
Further, the interest in high
throughput screening (HTS) technologies in the United States has increased
drastically in academic research in recent years. Also, a comprehensive
database of academic screening centers is available; these centers are hosted
by the Society for Biomolecular Sciences. This not only provides HTS resources
to the academia, but also helps identify both probes and leads for drug
discovery. Also, these centers promote open-source data sharing of small
molecule screening data. Moreover, the rising prevalence of chronic diseases
has also added to the demand for potential drugs in the US. This rising demand
is expected to bolster the market for drug discovery in the future.
Antares Pharma Inc is a specialty pharmaceutical company. It focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The company is engaged in developing, manufacturing, and commercializing therapeutic products using its drug delivery systems. Antares is headquartered in New Jersey, the United States.
Market By Type, Application, E ..
VIEW REPORT
Market By Device Type, Therape ..
VIEW REPORT
Market By Type, Application, T ..
VIEW REPORT
Market By Technology, Applicat ..
VIEW REPORT
Market By Application, Type, E ..
VIEW REPORT
Market by Therapeutics, Diagno ..
VIEW REPORT
Market by Type, Application, E ..
VIEW REPORT1. NORTH
AMERICA DRUG DISCOVERY MARKET - SUMMARY
2. INDUSTRY
OUTLOOK
2.1. MARKET
DEFINITION
2.2. PORTER'S
FIVE FORCES MODEL
2.2.1. THREATS
OF NEW ENTRANTS
2.2.2. THREAT
OF SUBSTITUTE PRODUCTS
2.2.3. BARGAINING
POWER OF BUYERS
2.2.4. BARGAINING
POWER OF SUPPLIERS
2.2.5. COMPETITIVE
RIVALRY
2.3. COVID-19
AND ITS IMPACT ON DRUG DISCOVERY MARKET
2.4. PESTLE
OUTLOOK
2.5. REGULATORY
FRAMEWORK
2.6. VALUE
CHAIN OUTLOOK
2.7. MARKET
ATTRACTIVENESS INDEX
2.8. KEY
INSIGHT
2.9. MARKET
DRIVERS
2.9.1. GROWING
AGED POPULATION
2.9.2. TECHNOLOGICAL
ADVANCEMENTS
2.9.3. RISE
IN HEALTHCARE EXPENDITURE
2.9.4. SURGE
IN LIFESTYLE-ORIENTED DISEASES
2.10. MARKET RESTRAINTS
2.10.1. DELAY IN PRODUCT LAUNCHES
2.10.2. RESTRICTED GROWTH RATE DUE TO GENERIC DRUGS
2.11. MARKET OPPORTUNITIES
2.11.1. SIGNIFICANT INVESTMENT BY HEALTHCARE INDUSTRIES
IN IMPROVING BIG DATA ANALYTICAL CAPABILITIES
2.11.2. RISING DEMAND FOR SPECIALTY MEDICINES
2.12. MARKET CHALLENGES
2.12.1. STRINGENT GOVERNMENT REGULATIONS
3. DRUG
DISCOVERY MARKET OUTLOOK - BY DRUG TYPE
3.1. SMALL
MOLECULE DRUG
3.2. BIOLOGIC
DRUG
4. DRUG
DISCOVERY MARKET OUTLOOK - BY TECHNOLOGY
4.1. HIGH
THROUGHPUT SCREENING
4.2. BIOCHIPS
4.3. BIOINFORMATICS
4.4. PHARMACOGENOMICS
AND PHARMACOGENETICS
4.5. COMBINATORIAL
CHEMISTRY
4.6. NANOTECHNOLOGY
4.7. SPECTROSCOPY
4.8. METABOLOMICS
4.9. OTHER
TECHNOLOGIES
5. DRUG
DISCOVERY MARKET OUTLOOK - BY SERVICE
5.1. DRUG
METABOLISM AND PHARMACOKINETICS (DMPK) SERVICES
5.2. CHEMICAL
SERVICES
5.3. BIOLOGICAL
SERVICES
5.4. OTHER
PHARMACEUTICAL SERVICES
6. DRUG
DISCOVERY MARKET OUTLOOK - BY END-USER
6.1. RESEARCH
INSTITUTES
6.2. PHARMACEUTICAL
COMPANIES
6.3. CONTRACT
RESEARCH ORGANIZATIONS (CROS)
6.4. OTHER
END-USERS
7. DRUG
DISCOVER MARKET – NORTH AMERICA
7.1. COUNTRY
ANALYSIS
7.1.1. UNITED
STATES
7.1.2. CANADA
8. COMPANY
PROFILES
8.1. 3M
COMPANY
8.2. ABBOTT
LABORATORIES INC
8.3. AGILENT
TECHNOLOGIES INC
8.4. ANTARES
PHARMA INC
8.5. ASTRAZENECA
PLC
8.6. BAYER
AG
8.7. BECTON
DICKINSON & COMPANY (BD)
8.8. BOEHRINGER
INGELHEIM
8.9. ELI
LILY AND COMPANY
8.10. F HOFFMANN-LA ROCHE LTD
8.11. GLAXOSMITHKLINE LLC
8.12. JOHNSON & JOHNSON
8.13. MERCK & CO INC
8.14. NOVARTIS
8.15. PFIZER INC
8.16. SANOFI
9. RESEARCH
METHODOLOGY & SCOPE
9.1. RESEARCH
SCOPE & DELIVERABLES
9.1.1. OBJECTIVES
OF STUDY
9.1.2. SCOPE
OF STUDY
9.2. SOURCES
OF DATA
9.2.1. PRIMARY
DATA SOURCES
9.2.2. SECONDARY
DATA SOURCES
9.3. RESEARCH
METHODOLOGY
9.3.1. EVALUATION
OF PROPOSED MARKET
9.3.2. IDENTIFICATION
OF DATA SOURCES
9.3.3. ASSESSMENT
OF MARKET DETERMINANTS
9.3.4. DATA
COLLECTION
9.3.5. DATA
VALIDATION & ANALYSIS
TABLE 1 NORTH AMERICA DRUG DISCOVERY MARKET, BY COUNTRY, 2019-2028 ($
MILLION)
TABLE 2 NORTH AMERICA DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2019-2028
($ MILLION)
TABLE 3 NORTH AMERICA DRUG DISCOVERY MARKET, BY DRUG TYPE, 2019-2028
($ MILLION)
TABLE 4 NORTH AMERICA DRUG DISCOVERY MARKET, BY SERVICE, 2019-2028 ($
MILLION)
TABLE 5 NORTH AMERICA DRUG DISCOVERY MARKET, BY END-USER, 2019-2028
($ MILLION)
TABLE 6 NORTH AMERICA DRUG DISCOVERY MARKET, BY
COUNTRY, 2019-2028 ($ MILLION)
FIGURE 1 NORTH AMERICA DRUG DISCOVERY MARKET, BY
REGION, 2019-2028 ($ MILLION)
FIGURE 2 NORTH AMERICA DRUG DISCOVERY MARKET, BY
SMALL MOLECULE DRUG, 2019-2028 ($ MILLION)
FIGURE 3 NORTH AMERICA DRUG DISCOVERY MARKET, BY
BIOLOGIC DRUG, 2019-2028 ($ MILLION)
FIGURE 4 NORTH AMERICA DRUG DISCOVERY MARKET, BY
HIGH THROUGHPUT SCREENING, 2019-2028 ($ MILLION)
FIGURE 5 NORTH AMERICA DRUG DISCOVERY MARKET, BY
BIOCHIPS, 2019-2028 ($ MILLION)
FIGURE 6 NORTH AMERICA DRUG DISCOVERY MARKET, BY
BIOINFORMATICS, 2019-2028 ($ MILLION)
FIGURE 7 NORTH AMERICA DRUG DISCOVERY MARKET, BY
PHARMACOGENOMICS AND PHARMACOGENETICS, 2019-2028 ($ MILLION)
FIGURE 8 NORTH AMERICA DRUG DISCOVERY MARKET, BY
COMBINATORIAL CHEMISTRY, 2019-2028 ($ MILLION)
FIGURE 9 NORTH AMERICA DRUG DISCOVERY MARKET, BY
NANOTECHNOLOGY, 2019-2028 ($ MILLION)
FIGURE 10 NORTH AMERICA DRUG DISCOVERY MARKET, BY
SPECTROSCOPY, 2019-2028 ($ MILLION)
FIGURE 11 NORTH AMERICA DRUG DISCOVERY MARKET, BY
METABOLOMICS, 2019-2028 ($ MILLION)
FIGURE 12 NORTH AMERICA DRUG DISCOVERY MARKET, BY OTHER
TECHNOLOGIES, 2019-2028 ($ MILLION)
FIGURE 13 NORTH AMERICA DRUG DISCOVERY MARKET, BY DRUG
METABOLISM AND PHARMACOKINETICS (DMPK) SERVICES, 2019-2028 ($ MILLION)
FIGURE 14 NORTH AMERICA DRUG DISCOVERY MARKET, BY
CHEMICAL SERVICES, 2019-2028 ($ MILLION)
FIGURE 15 NORTH AMERICA DRUG DISCOVERY MARKET, BY
BIOLOGICAL SERVICES, 2019-2028 ($ MILLION)
FIGURE 16 NORTH AMERICA DRUG DISCOVERY MARKET, BY OTHER
PHARMACEUTICAL SERVICES, 2019-2028 ($ MILLION)
FIGURE 17 NORTH AMERICA DRUG DISCOVERY MARKET, BY
RESEARCH INSTITUTES, 2019-2028 ($ MILLION)
FIGURE 18 NORTH AMERICA DRUG DISCOVERY MARKET, BY
PHARMACEUTICAL COMPANIES, 2019-2028 ($ MILLION)
FIGURE 19 NORTH AMERICA DRUG DISCOVERY MARKET, BY
CONTRACT RESEARCH ORGANIZATIONS (CROS), 2019-2028 ($ MILLION)
FIGURE 20 NORTH AMERICA DRUG DISCOVERY MARKET, BY OTHER
END-USERS, 2019-2028 ($ MILLION)
FIGURE 21 UNITED STATES DRUG DISCOVERY MARKET 2019-2028
($ MILLION)
FIGURE 22 CANADA DRUG DISCOVERY MARKET 2019-2028 ($ MILLION)